Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 7,392 matching trials from the live ClinicalTrials.gov search.
Conditions
Bladder Cancer
Interventions
Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Multiple Dose PK

NCT04327765
Conditions
Healthy
Interventions
0.5mg AZ-010, 1mg AZ-010, 3mg AZ-010
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
COVID-19, SARS-CoV-2
Interventions
CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more
Conditions
Lymphoma
Interventions
Atezolizumab, Obinutuzumab, Tazemetostat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Duarte, California • Fort Wayne, Indiana • Hackensack, New Jersey + 4 more
Conditions
Glioblastoma
Interventions
INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
Biological · Radiation · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 15 more
Conditions
Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
erlotinib hydrochloride, cisplatin, intensity-modulated radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-80948543
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Duarte, California • New York, New York • Nashville, Tennessee + 3 more
Conditions
Primary CNS Lymphoma
Interventions
Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI)
Drug · Procedure
Lead sponsor
James Rubenstein
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy Volunteers
Interventions
TAK-788, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Conditions
Non Small Cell Lung Cancer
Interventions
Zanidatamab, Zongertinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
Interventions
Surgery, Chemoradiation, Observation, Post-operative radiation
Procedure · Combination Product · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
GRN163L
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Harvey, Illinois • Indianapolis, Indiana
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Flu Vaccine Doses in Children

NCT01164553
Conditions
Influenza
Interventions
Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 35 Months
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Graft Versus Host Disease, Allogeneic Hematopoietic Cell Transplant Recipient
Interventions
Regulatory T Cells
Biological
Lead sponsor
Laura Johnston
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Alcohol-Related Disorders
Interventions
Dihydromyricetin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Melanoma, Neuroblastoma, Sarcoma
Interventions
124I-Humanized 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric
Interventions
BMS-986158, BMS-986378
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Durham, North Carolina + 2 more
Conditions
Age-Related Macular Degeneration
Interventions
ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
150
States / cities
Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
Conditions
Endometrial Cancer
Interventions
Letrozole, Abemaciclib, LY3023414, Metformin, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Prostatic Neoplasm
Interventions
177Lu-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more